Polymorphic MLH1 and Risk of Cancer After Methylating Chemotherapy for Hodgkin Lymphoma

Journal of Medical Genetics - United Kingdom
doi 10.1136/jmg.2007.053850
Full Text
Abstract

Available in full text

Categories
Genetics
Date
Authors
Publisher

BMJ

Related search

Occurrence of Sarcoidosis After Chemotherapy for Non-Hodgkin Lymphoma

Korean Journal of Internal Medicine
Internal Medicine
2016English

Non-Hodgkin Lymphoma Secondary to Cancer Chemotherapy

Cancer Epidemiology Biomarkers and Prevention
MedicineEpidemiologyOncology
2007English

Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma

Advances in Hematology
Hematology
2011English

EBV-Positive Plasmablastic Lymphoma Mimicking Reactive Lymphadenopathy Versus Recurrent Hodgkin Lymphoma Following Chemotherapy for Stage II Classical Hodgkin Lymphoma

Journal of Tumour Research & Reports
2018English

Eruptive Pseudoangiomatosis in a Child Undergoing Chemotherapy for Hodgkin Lymphoma

Pediatric Blood and Cancer
OncologyChild HealthHematologyPerinatologyMedicinePediatrics
2011English

Chemotherapy or Combined Modality Therapy for Early-Stage Hodgkin Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Risk of HBV Liver Disease in Isolated antiHbc Patients Receiving Immuno-Chemotherapy for Non Hodgkin Lymphoma

Haematologica
Hematology
2008English

Occupation and the Risk of Non-Hodgkin Lymphoma

Cancer Epidemiology Biomarkers and Prevention
MedicineEpidemiologyOncology
2007English

Limited-Stage Hodgkin Lymphoma: Optimal Chemotherapy and the Role of Radiotherapy

American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting
Medicine
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy